JAZZ News and Press, Jazz Pharmaceuticals plc From 10/06/23

Originally published in Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report NORTHAMPTON, MA / ACCESSWIRE / October 6, 2023 / A Letter From Our Chairman of the Board and Chief Executive Officer Bruce C. Cozadd I am pleased to share Jazz's 2022 Corporate Sustainabili...

2023-09-29 13:05:39 ET More on AbbVie, Alnylam, etc. AbbVie: Company Vs. Stock, A Gentle Facelift Would Be Nice (Technical Analysis) AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths AbbVie Inc. (ABBV) Morgan Stanley 21st Annual Global Healthcare Brokers...

2023-09-27 14:38:11 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cannabis stocks are undoubtedly a booming opportunity. Many investors consider this sector as a great opportunity to invest and compare it with the artificial intelligence and robotics se...

2023-09-22 10:15:25 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group –  Despite the potential federal funding challenges due to the recent debt ceiling deal , optimism in the b...

2023-09-22 09:29:56 ET More on Jazz Pharma Seeking Alpha’s Quant Rating on Jazz Pharmaceuticals Historical earnings data for Jazz Pharmaceuticals Financial information for Jazz Pharmaceuticals Jazz Pharmaceuticals: Depressed Valuation Opens Up Potentia...

Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma PR Newswire DUBLIN , Sept. 21, 2023 /PRNewswire/ -- Ja...

2023-09-20 08:30:53 ET NetworkNewsWire Editorial Coverage New York, NY – September 20, 2023 – More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...

Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences PR Newswire DUBLIN , Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor confere...

2023-09-12 07:40:45 ET More on Jazz Pharmaceuticals Seeking Alpha’s Quant Rating on Jazz Pharmaceuticals Jazz Pharmaceuticals: Depressed Valuation Opens Up Potential Jazz Pharmaceuticals: Xywav Debate Continued Drag On Equity Performance Jazz Pharma wi...